Prescription frequency and predictors for the use of novel direct oral anticoagulants for secondary stroke prevention in the first year after their marketing in Europe - a multicentric evaluation

International Journal of Stroke

Volumn 9, Issue 5, 2014, Pages 569-575

  Luger, Sebastian ^a   Hohmann, Carina ^b   Kraft, Peter ^c   Halmer, Ramona ^d   Gunreben, Ignaz ^c   Neumann Haefelin, Tobias ^b   Kleinschnitz, Christoph ^c   Walter, Silke ^d   Haripyan, Veronika ^a   Steinmetz, Helmuth ^a   Foerch, Christian ^a   Pfeilschifter, Waltraud ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b KLINIKUM FULDA   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

Adherence; Atrial fibrillation; Safety; Stroke; Thrombin; Xa

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; CREATININE; DABIGATRAN; RIVAROXABAN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTROLLED STUDY; CONVALESCENCE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG MARKETING; EUROPE; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY PREVENTION; TERTIARY HEALTH CARE; TRANSIENT ISCHEMIC ATTACK; AGE; ATRIAL FIBRILLATION; BLOOD; BRAIN ISCHEMIA; CLINICAL TRIAL; COHORT ANALYSIS; ISCHEMIC ATTACK, TRANSIENT; KIDNEY; MARKETING; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; STROKE; TERTIARY CARE CENTER;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COHORT STUDIES; CREATININE; EUROPE; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; KIDNEY; MALE; MARKETING; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; STROKE; TERTIARY CARE CENTERS;

EID: 84902076816     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12289     Document Type: Article

References (20)

1. Connolly SJ, Ezekowitz MD, Yusuf S etal. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
2. Patel MR, Mahaffey KW, Garg J etal. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
3. Granger CB, Alexander JH, McMurray JJ etal. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
4. Available at ClinicalTrials.gov (accessed 24 September 2013).
5. Diener HC, Connolly SJ, Ezekowitz MD etal. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9:1157-1163.
6. Hankey GJ, Patel MR, Stevens SR etal. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11:315-322.
7. FDA drug safety communication: safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). Available at http://www.fda.gov/drugs/drugsafety/ucm282724.htm (accessed 19 January 2014).
8. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368:1272-1274.
9. Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Adv Inflamm Res 1984; 6:1-7.
10. Pfeilschifter W, Luger S, Brunkhorst R, Lindhoff-Last E, Foerch C. The gap between trial data and clinical practice - an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. Cerebrovasc Dis 2013; 36:115-119.
11. Furie KL, Kasner SE, Adams RJ etal. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:227-276.
12. Lewis WR, Fonarow GC, Grau-Sepulveda MV etal. Improvement in use of anticoagulation therapy in patients with ischemic stroke: results from Get With The Guidelines-Stroke. Am Heart J 2011; 162:692-699.
13. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57:173-180.
14. Castillo J, Leira R, Garcia M etal. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004; 35:520-526.
15. Indredavik B, Rohweder G, Lydersen S. Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation. J Int Med 2005; 258:133-144.
16. Hylek EM, Go AS, Chang Y etal. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019-1026.
17. O'Donnell M, Oczkowski W, Fang J etal. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol 2006; 5:749-754.
18. Schwammenthal Y, Bornstein N, Schwammenthal E etal. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]). Am J Cardiol 2010; 105:411-416.
19. Barco S, Cheung YW, Eikelboom JW, Coppens M. New oral anticoagulants in elderly patients. Best Pract Res Clin Haematol 2013; 26:215-224.
20. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125:2298-2307.